


Hypericin-d₂

Cat. No.:	HY-N0453S1
Molecular Formula:	C ₃₀ H ₁₄ D ₂ O ₈
Molecular Weight:	506.46
Target:	Apoptosis; Influenza Virus
Pathway:	Apoptosis; Anti-infection
Storage:	<div>Powder -20°C 3 years</div> <div>In solvent -80°C 6 months</div> <div> -20°C 1 month</div>



BIOLOGICAL ACTIVITY

Description	Hypericin-d ₂ is deuterium labeled Hypericin.
In Vitro	<p>Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
- [2]. Agostinis P et al. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol. 2002 Mar;34(3):221-41.
- [3]. Hwang MS et al. Inhibition of c-erbB-2 expression and activity in human ovarian carcinoma cells by hypericin. Anticancer Res. 2001 Jul-Aug;21(4A):2649-55.
- [4]. Lenard J et al. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):158-62.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA